Physicians' Academy for Cardiovascular Education
The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.
In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.
A pooled analysis of ORION-9, -10 and -11 offers early insights into the potential of inclisiran to lower CV risk in high-risk patients with elevated LDL-c levels, while results of dedicated CV outcomes trials are awaited.
AHA 2022 High CV risk patients in ORION-1 were invited to participate in open-label extension study with inclisiran -the ORION-3 study. What is the 4-year long-term efficacy and safety of inclisiran in these patients?
RCTs among adults with HeFH show that treatment with evolocumab does not lead to cognitive dysfunction. But does the same hold true for pediatric patients with HeFH? This post-hoc analysis of data from the HAUSER-RCT study offers more insight.
Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.
What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.
Raul Santos and Maciej Banach talk about the safety of PCSK9 mAbs and of very low cholesterol levels, and discuss the importance of patient education to improve adherence.
The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?
How can we make the best choices for optimal, affordable and sustainable care for patients with high CV risk due to multiple risk factors? Prof. Stroes illustrates the challenge of choosing.
Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.
Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.
